1-7 of 7
Kwok-Leung Cheung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5469.
https://doi.org/10.1158/1078-0432.CCR-22-3568
Published: 15 December 2022
View article titled, Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Journal Articles

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4242–4249.
https://doi.org/10.1158/1078-0432.CCR-19-3387
Published: 14 August 2020
View article titled, A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer
Open the PDF for A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER<sup>+</sup> HER2<sup>−</sup> Primary Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

John F.R. Robertson, Robert E. Coleman, Kwok-Leung Cheung, Abigail Evans, Chris Holcombe, Anthony Skene, Daniel Rea, Samreen Ahmed, Ali Jahan, Kieran Horgan, Petra Rauchhaus, Roberta Littleford, S.Y. Amy Cheung, Marie Cullberg, Elza C. de Bruin, Loumpiana Koulai, Justin P.O. Lindemann, Martin Pass, Paul Rugman, Gaia Schiavon, Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M.W. Gee
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1574–1585.
https://doi.org/10.1158/1078-0432.CCR-19-3053
Published: 01 April 2020
View article titled, Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Open the PDF for Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) in another window
Includes: Supplementary data
Journal Articles

Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition

Xian Chen, Kwang-Huei Low, Angela Alexander, Yufeng Jiang, Cansu Karakas, Kenneth R. Hess, Jason P.W. Carey, Tuyen N. Bui, Smruthi Vijayaraghavan, Kurt W. Evans, Min Yi, D. Christian Ellis, Kwok-Leung Cheung, Ian O. Ellis, Siqing Fu, Funda Meric-Bernstam, Kelly K. Hunt, Khandan Keyomarsi
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6594–6610.
https://doi.org/10.1158/1078-0432.CCR-18-1446
Published: 13 December 2018
View article titled, Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Open the PDF for Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition in another window
Includes: Supplementary data
Journal Articles

BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer

Chun Gong, Ellen P.S. Man, Ho Tsoi, Terence K.W. Lee, Paul Lee, Sai-Ting Ma, Lai-San Wong, Mai-Yee Luk, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Eric W.-F. Lam, Kwok-Leung Cheung, Ui-Soon Khoo
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3681–3691.
https://doi.org/10.1158/1078-0432.CCR-17-2259
Published: 31 July 2018
View article titled, BQ323636.1, a Novel Splice Variant to <em>NCOR</em>2, as a Predictor for Tamoxifen-Resistant Breast Cancer
Open the PDF for BQ323636.1, a Novel Splice Variant to <em>NCOR</em>2, as a Predictor for Tamoxifen-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Kelly K. Hunt, Cansu Karakas, Min Jin Ha, Anna Biernacka, Min Yi, Aysegul A. Sahin, Opoku Adjapong, Gabriel N. Hortobagyi, Melissa L. Bondy, Patricia A. Thompson, Kwok Leung Cheung, Ian O. Ellis, Sarah Bacus, W. Fraser Symmans, Kim-Anh Do, Khandan Keyomarsi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 2991–3002.
https://doi.org/10.1158/1078-0432.CCR-16-2217
Published: 14 June 2017
View article titled, Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Open the PDF for Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

Nigel J. Bundred, Angela Cramer, Julie Morris, Lorna Renshaw, Kwok-Leung Cheung, Pamela Flint, Rachael Johnson, Oliver Young, Göran Landberg, Sue Grassby, Lorraine Turner, Andrew Baildam, Lester Barr, J. Michael Dixon
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1605–1612.
https://doi.org/10.1158/1078-0432.CCR-09-1623
Published: 28 February 2010
View article titled, Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma <em>In situ</em> Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial
Open the PDF for Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma <em>In situ</em> Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial in another window